• small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

RSS Content

MiMedx To Webcast Its Investor's Day Conference on November 30, 2017

MARIETTA, Ga., Nov. 8, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that it will be hosting and webcasting its Investor's Day Conference on Thursday, November 30, 2017. The conference will be held in New York City.   

The Company reported that "Pete" Petit, Chairman and CEO; Bill Taylor, President and COO; Chris Cashman, EVP and Chief Commercialization Officer; Debbie Dean, Executive Vice President; Mike Senken, Chief Financial Officer; Mark Landy, Senior Vice President, Strategic Initiatives; and Gloria Matthews, Senior Vice President, Research and Development will be presenting during the November 30th conference. Also present will be Donald Fetterolf, M.D., Chief Medical Officer; Thomas Koob, PhD, Chief Scientific Officer; and other members of MiMedx senior management. Physicians who are clinical study Principal Investigators (PIs), and Key Opinion Leaders (KOLs) will also be in attendance for presentations and panel discussions.

The Investor's Day presentations will provide a comprehensive overview and update on the numerous strategic and tactical initiatives undertaken by the Company, as well as dialog on related details during the planned panel discussions and question and answer session. The panel discussions and presentations will address details related to:

  • Strategic plans for 2018 and beyond;
  • Biopharmaceutical initiative update;
  • Status of Investigational New Drug (IND) and Biologic License Applications (BLA);
  • Overview and update of Randomized Controlled Trials (RCTs) activity and data;
  • Biopharmaceutical pipeline update and potential pipeline products;
  • Competitive differentiation and significant benefits of the Company's Biopharmaceutical Products;
  • Growth opportunities in Pain Management including Tendonitis, Osteoarthritis and others;
  • Regulatory and  reimbursement strategies; 
  • Financial update; and
  • Presentation of certain case studies by physician PIs and KOLs.

Parker H. "Pete" Petit, Chairman and CEO stated, "We have made rapid progress in advancing our biopharma strategy, growing our compendium of scientific and clinical results, developing expanded market opportunities for our current and future product offerings, and enlarging the Company's substantial asset base to drive our planned growth. We look forward to sharing this information with investors later this month."

In-person attendance at the presentations will be by invitation only. The webcast will be a listen-only simulcast of the presentations beginning at 11:00 AM Eastern Time and concluding at approximately 2:30 PM Eastern Time. The webcast will be available on-line at the Company's website www.mimedx.com.  An on-line replay will be available approximately one hour following the conclusion of the live webcast.  The replay will also be available on the Company's website at www.mimedx.com.

About MiMedx

MiMedx® is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts.   MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.  MiMedx is the leading supplier of placental tissue, having supplied over 1,000,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.

Important Cautionary Statement

This press release includes forward-looking statements including that the Company's biopharmaceutical strategy, compendium of scientific and clinical results, current and future product offerings, and asset base will drive growth. These statements also may be identified by words such as "believe," "except," "may," "plan," "potential," "will" and similar expressions, and are based on our current beliefs and expectations. Forward-looking statements are subject to significant risks and uncertainties, and we caution investors against placing undue reliance on such statements.  Actual results may differ materially from those set forth in the forward-looking statements. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the Company's growth may not materialize as planned.  For more detailed information on the risks and uncertainties, please review the Risk Factors section of our most recent annual report or quarterly report filed with the Securities and Exchange Commission.  Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statement.

View original content:http://www.prnewswire.com/news-releases/mimedx-to-webcast-its-investors-day-conference-on-november-30-2017-300552173.html

SOURCE MiMedx Group, Inc.

Investor Contact: COCKRELL GROUP, Rich Cockrell, 877-889-1972, investorrelations@thecockrellgroup.com, cockrellgroup.com; Press Contact: Michael Senken, Phone: (770) 651-9100

Products

CONTACT US

888.543.1917